We presume that these key hub genes identified by a series of bioinformatics analyses on DEGs between tumor samples and anti-VEGF-resistant samples are probably related to the sensitivity of glioblastomas to anti-VEGF therapy. This evidence concerns the gene VEGFA and neoplasm.